{
    "organizations": [],
    "uuid": "c62b8645517fbc1ee5fd9f1c9adb5d5813f71254",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-htg-molecular-announces-third-stat/brief-htg-molecular-announces-third-statement-of-work-for-new-clinical-assay-development-program-idUSFWN1PB13J",
    "ord_in_thread": 0,
    "title": "BRIEF-HTG Molecular Announces Third Statement Of Work For New Clinical Assay Development Program",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 16 (Reuters) - HTG Molecular Diagnostics Inc:\n* HTG MOLECULAR ANNOUNCES THIRD STATEMENT OF WORK FOR NEW CLINICAL ASSAY DEVELOPMENT PROGRAM\n* HTG MOLECULAR - THE THIRD STATEMENT OF WORK IS UNDER ITS MASTER ASSAY DEVELOPMENT, COMMERCIALIZATION & MANUFACTURING AGREEMENT WITH A UNIT OF QIAGEN NV Source text for Eikon: Further company coverage:\n ",
    "published": "2018-01-16T21:14:00.000+02:00",
    "crawled": "2018-01-17T20:16:05.045+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "htg",
        "molecular",
        "diagnostics",
        "inc",
        "htg",
        "molecular",
        "announces",
        "third",
        "statement",
        "work",
        "new",
        "clinical",
        "assay",
        "development",
        "program",
        "htg",
        "molecular",
        "third",
        "statement",
        "work",
        "master",
        "assay",
        "development",
        "commercialization",
        "manufacturing",
        "agreement",
        "unit",
        "qiagen",
        "nv",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}